Abbott’s Freestyle Libre 2 Gains Medicare Coverage
FreeStyle Libre 2 is the only integrated continuous glucose monitoring system that continuously measures the user's blood glucose without fingersticks.
You may also be interested in...
Analyst Larry Biegelsen expects Abbott’s CGM move into the consumer market could open a large new marketing opportunity.
Abbott’s medical device sales were down about 20% year-over-year in the second quarter of 2020, but diagnostics sales were up 7%. Procedure trends at the end of the second quarter suggest that demand for devices will soon recover to pre-pandemic levels.
Research presented at this year’s virtual American Diabetes Association meeting demonstrated the benefits of continuous glucose monitoring for those with type 2 diabetes not taking insulin. Mahmood Kazemi, divisional VP for global medical and scientific affairs at Abbott’s diabetes care tells Medtech Insight how he sees CGM technology transforming the future of diabetes management.